First Trust Health Care AlphaDEXFXH

The First Trust Health Care AlphaDEX ETF (FXH) is a US-listed wrapper that tracks the StrataQuant Health Care Index, a rules-based selection of roughly 150 health-care stocks chosen for growth and value factors. The fund’s mandate is to deliver the index’s return minus a 0.63% annual fee-nothing more, nothing less. The SEC filing shows FXH as a standard open-end fund with no leverage or inverse mechanics, so investors are buying the index and paying the issuer to manage the wrapper. The fund’s AUM and daily volume are visible on exchange data, but the issuer’s marketing never explains why an investor should prefer this index over the next health-care ETF, other than the fact that the issuer charges a fee to do it.

FXH trades on NASDAQ like a stock, but it is not a biotech start-up with a blockbuster drug. It is a portfolio of health-care companies-device makers, insurers, drug distributors, diagnostics firms, and a handful of biotechs-selected by a quantitative screen and then handed to a fee-collecting intermediary. The index provider’s methodology is filed with the SEC, but the filing does not promise relative strength; it only promises replication. The fund’s expense ratio is the only figure that is guaranteed to compound against the basket every year.

The SEC EDGAR filing for FXH confirms the fund’s expense ratio at 0.63% and describes the index as a quantitative selection of US health-care stocks, with reconstitutions and rebalances governed by rules published separately. The filing does not guarantee the fund will beat its benchmark after fees, nor does it state why an investor should expect the screen to persistently relative strength. The fund’s performance history is available on NASDAQ, but the evidence does not prove persistence, skill, or luck.

FXH’s chart is available on NASDAQ’s platform, but the renderer will not place trading levels here. The chart’s shape is a function of the underlying basket’s price action, the fund’s expense drag, and the issuer’s decision to keep the fee unchanged. The fund’s liquidity is a reflection of the average daily volume of its holdings, not the issuer’s balance sheet. The NASDAQ market data page shows the ticker’s trading activity, but it does not show the fund’s true cost of ownership beyond the expense ratio.

What changed this week? Nothing in the issuer’s filings or exchange data suggests a shift in mandate, holdings, or fees. The fund continues to collect 0.63% while the index rolls on. The evidence does not show a material catalyst, a filing update, or a change in the index methodology. The NASDAQ page and SEC filing remain the only public rail for facts about FXH. If the index provider or issuer were to publish a rules change, a performance attribution, or a fee reduction, that would deepen the file. Until then, the fund is a fee-bearing sleeve over a static screen.